What LEAP Meant for Food Allergy
In 2015, a study changed the entire understanding of peanut allergen exposure. Physicians are still trying to understand how to implement it today.
Related Articles
Naps at Noon Linked to Mortality Risk in Older Adults, with Chenlu Gao, PhD
A study presented at SLEEP 2025 found longer and more variable napping patterns are associated with increased all-cause mortality in middle-to-older aged adults.
FDA Extends Review Period of Ruxolitinib Cream for Children with Atopic Dermatitis
This update by FDA officials extends the review period for ruxolitinib cream as a treatment for atopic dermatitis in children aged 2-11 years.
Updates in Obesity Hypoventilation Syndrome Diagnosis, with Atul Malhotra, MD
At SLEEP 2025, Malhotra shared updates on diagnosing and managing OHS, including the role of bicarbonate, PAP use, and weight loss.
HCPLive – Clinical news for connected physicians
HCPLive is a clinical news and information portal, offering physicians specialty and disease-specific resources, conference coverage, and interviews.
Anaphylaxis | Medical News & Expert Insight | HCPLive
The anaphylaxis condition center is a comprehensive resource for clinical news and expert insights on anaphylaxis. Read more at HCPLive.
Naps at Noon Linked to Mortality Risk in Older Adults, with Chenlu Gao, PhD
A study presented at SLEEP 2025 found longer and more variable napping patterns are associated with increased all-cause mortality in middle-to-older aged adults.
Emerging Treatment Options in Patients With Difficult-to-Treat Hypertension
A panelist discusses how resistant hypertension remains a significant clinical challenge requiring accurate diagnosis, lifestyle and pharmacologic optimization, and emerging therapies such as aprocitentan to…
FDA Approves Dupilumab (Dupixent) for Bullous Pemphigoid in Adult Patients
Dupilumab (Dupixent) approved as the first targeted therapy for bullous pemphigoid, marking 8th indication for diseases with type 2 inflammation.
Classifying Obesity as a Chronic Disease with W. Timothy Garvey, MD
The recent Lancet Commission on Obesity has repositioned the former risk factor as a disease, indicating and emphasizing a variety of complications.
FDA Approves Dupilumab (Dupixent) for Bullous Pemphigoid in Adult Patients
Dupilumab (Dupixent) approved as the first targeted therapy for bullous pemphigoid, marking 8th indication for diseases with type 2 inflammation.